887468-75-9

Upstream product

• 887468-56-6 trifluoro-methanesulfonic acid 7-methoxy-3-(4-methoxy-phenyl)-4-oxo-3,4-dihydro-quinazolin-5-yl ester 
• 13061-96-6 dihydroxy-methyl-borane 
• 40891-33-6 3,5-dimethoxyaniline hydrochloride 
• 21577-57-1 2-amino-4,6-dimethoxybenzoic acid 
• 21544-81-0 4,6-dimethoxyindoline-2,3-dione 
• 887468-62-4 2-amino-4,6-dimethoxy-N-(4-methoxyphenyl)benzamide 
• 628686-89-5 5,7-dimethoxy-3-(4-methoxyphenyl)-4(3H)-quinazolinone 
• 63920-75-2 1,2-dihydro-5,7-dimethoxy-3,1-benzoxazine-2,4-dione 
• 628686-76-0 5,7-dimethoxy-3,1-benzoxazine-4-one 

Downstream Products

• 887468-94-2 7-methoxy-3-(4-methoxy-phenyl)-5-methyl-3H-quinazoline-4-thione 

Relevant academic research and scientific papers

Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators

On the basis of the structure of genistein, a new series of 3-arylquinazolines was prepared and tested for their estrogen receptor (ER) α and β affinities. 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4(3H)- quinazolinone (1aa) acts as an agonist on both ER subtypes. It has 62-fold higher binding affinity [IC50(ERβ) = 179 nM] and 38-fold higher functional potency in a transcription assay [EC50(ERβ) = 76 nM] with ERβ than with ERα, thus improving upon the selectivity of genistein. All of the analogues showed preferential binding affinity for ERβ. Many are also more potent in activating transcription by ERβ than by ERα. Transformation of the C=O functionality at position 4 into a C=S group provided 5,7-dihydroxy-3-(4-hydroxyphenyl)-4(3H)-quinazolinethione (1ba), which acts as an agonist on both ER subtypes but has 56-fold higher binding affinity for ERβ over ERα [IC50(ERβ) = 47 nM] and 215-fold higher potency in the transcription assay [EC50(ERβ) = 13 nM]. These ERβ-selective compounds may represent valuable tools in understanding the differences in structure and biological function of ERβ and ERα.

C-5 SUBSTITUTED QUINAZOLINONE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR BETA MODULATORS

The present application describes compounds according to Formula (I), wherein Q, R1, R2 and X are described herein, that are useful as Estrogen Receptor Beta (ERβ) modulators. Additionally, the present application describes pharmaceutical compositions containing the compounds according to Formula (I) and optionally additional therapeutic agents. Finally, the present application describes methods utilizing the compounds according to Formula (I) for modulating the function of ERβ in the treatment of diseases and disorders associated with ERβ such as, for example, bone disorders; cardiovascular diseases; hypercholesterolemia; hypertriglyceridemia; vasomotor disorders; urogenital disorders; prostatic hypertrophy; endometrial hyperplasia; cancer and central nervous system disorders, such as, neurodegenerative disorders.